- Home
- ACRS
as 03-28-2025 4:00pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 170.9M | IPO Year: | 2015 |
| Target Price: | $11.67 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $5.17 | Next Earning Date: | 05-06-2025 |
| Revenue: | $18,720,000 | Revenue Growth: | -40.09% |
| Revenue Growth (this year): | -51.07% | Revenue Growth (next year): | -8.05% |
Latest Aclaris Therapeutics Inc. News
ACRS Breaking Stock News: Dive into ACRS Ticker-Specific Updates for Smart Investing
TipRanks
10 days ago
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald
GlobeNewswire
25 days ago
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Simply Wall St.
25 days ago
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year
Simply Wall St.
25 days ago
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
a month ago
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
a month ago
Aclaris: Q4 Earnings Snapshot
GlobeNewswire
a month ago
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
a month ago
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Compare ACRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRS Aclaris Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.